Mri systems brachytherapy prostate technology c4 imaging sirius mri marker

December 11, 2013 — C4 Imaging LLC announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its first product, the Sirius MRI Marker. The positive-signal magnetic resonance imaging (MRI) marker will be used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant MRI procedure.
 
Brachytherapy, or radioactive seed implantation, is a standard option for the curative treatment of prostate cancer. Brachytherapy involves implanting around 100 radioactive seeds into the prostate. Its popularity has increased due to its effectiveness, convenience, relatively low incidence of erectile dysfunction and minimal invasiveness [1]. Radiation released from the seeds penetrates the surrounding prostate tissue at a limited distance, with most of the radiation concentrated within the prostate. Outcomes after brachytherapy depend greatly on the quality of the implant: eight-year prostate-specific antigen (PSA) relapse-free survival rates of 93 percent for high-quality implants versus 76 percent for low-quality implants have been reported [2].
 
"A Positive-Signal MRI marker can enhance seed detection. This represents a significant advancement for prostate brachytherapy," said Steven Frank M.D., founder and chairman, C4 Imaging. "If seeds can be readily localized with MRI, it would lead to more effective treatment and better patient outcomes."
 
"The encapsulation of a contrast agent within a permanently implantable device allows positive MRI seed localization after brachytherapy to be offered to more than 200,000 men diagnosed with prostate cancer in the U.S. each year [3]," said Andrew Bright, president and CEO, C4 Imaging.
 
"With our 510(k) now cleared, we're actively pursuing options for supplying Sirius to physicians treating prostate cancer in the U.S., as well as seeking regulatory clearance in Canada and Europe,” Bright added.
 
For more information: www.c4imaging.com
 
References
[1] Frank SJ, et al. American College of Radiology Appropriateness Criteria Permanent Source Brachytherapy for Prostate Cancer. Brachytherapy. 2011; 10(5): 357-362.
[2] Zelefsky MJ, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int. J.   Radiat. Oncol. Biol. Phys. 2007; 67(2): 327-333.
[3] American Cancer Society. Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013.

Related Content

Feature | Radiation Oncology | By Melinda Taschetta-Millane

In a new 3-part video series on advancements in diagnostic radiology with Robert L. Bard, MD, PC, DABR, FASLMS ...

Time April 10, 2024
arrow
News | Radiology Business

April 4, 2024 — FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging ...

Time April 04, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | FDA

March 27, 2024 — SyntheticMR announced that its next-generation imaging solution, SyMRI 3D, has received FDA 510(k) ...

Time March 27, 2024
arrow
News | Artificial Intelligence

March 21, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care ...

Time March 21, 2024
arrow
Videos | Radiation Oncology

In the conclusion of this 3-part video series on recent advancements in diagnostic radiology, current editorial advisory ...

Time March 19, 2024
arrow
News | Artificial Intelligence

March 1, 2024 — Royal Philips, a global leader in health technology, and magnetic resonance imaging (MRI) software ...

Time March 01, 2024
arrow
News | Artificial Intelligence

February 26, 2024 — DeepHealth, Inc., one of the leading providers in healthcare radiology informatics, has today ...

Time February 26, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
News | FDA

February 15, 2024 — Merit Medical Systems, Inc., a global leader of healthcare technology, has received US Food and Drug ...

Time February 15, 2024
arrow
Subscribe Now